The Human Insulin Market size was valued at USD 19.21 billion in 2023 and is expected to reach USD 24.71 billion by 2031 and grow at a CAGR of 3.2% over the forecast period of 2024-2031.
A hormone called insulin controls the blood sugar level in the human body. Insulin is derived from the Latin word for island, insula. The beta cells in the pancreatic islets create this peptide hormone. The pancreatic islets receive 1-2% of the pancreas' volume and 10-15% of its blood flow. Blood sugar levels drop as blood sugar enters cells, signalling insulin to do the same. In order to ensure that energy is constantly available, even if you haven't eaten in a while, lower insulin levels instruct the liver to release stored blood sugar. Markets for human insulin are divided by product types, delivery methods, and geographic regions. The market is divided into traditional human insulin and analogue human insulin based on the kind of product. A form of insulin called traditional human insulin is produced in the pancreas of pigs or cows. A type of insulin produced in a lab is analogue human insulin. Compared to conventional human insulin, analogue human insulin is more efficient and has a longer duration of action.
The primary anabolic hormone in the human body is insulin. Insulin controls how carbs, proteins, and fats are metabolised in order to help the liver, skeletal muscle cells, and fats absorb glucose from the blood. These tissues take in glucose, which is then converted through glycogenesis, lipogenesis, or, in the case of the liver, both, into triglycerides (fats). High levels of insulin in the blood hardly ever impede the liver's ability to produce or secrete glucose. Although your blood glucose levels are above average, they are not yet high enough to be considered diabetic. This is called prediabetes. People who already have some insulin resistance or whose pancreatic beta cells are not producing enough insulin to keep blood sugar levels within the normal range are more likely to develop prediabetes.
Drivers:
Positive governmental initiatives and policies.
Increasing education and awareness.
There is an increasing level of public knowledge about diabetes. Numerous causes, including increasing media attention to diabetes, public health initiatives, and educational initiatives, are to blame for this. More people are receiving diabetes diagnoses as a result of greater knowledge of the ailment, which in turn has raised the demand for human insulin.
Restrain:
Low and middle-income countries have limited access.
inadequate knowledge of diabetes and insulin therapy.
Lack of knowledge about diabetes and insulin therapy can result in undertreatment and ineffective blood sugar management in some parts of the world.
Opportunity:
Increasing Attention Paid to Diabetes Prevention and Management.
The management and prevention of diabetes are receiving more attention from governments and healthcare organisations worldwide. Campaigns to raise diabetes awareness, early detection programmes, and increased access to diabetes care are a few examples of these initiatives. With an emphasis on encouraging diabetes control and boosting demand for insulin therapy, these initiatives offer a favourable climate for the human insulin market.
Challenge:
Human Insulin Market is also dependent on government regulations.
Alternative Therapies and Insulin Resistance.
With human insulin, controlling insulin resistance, a condition where the body becomes less receptive to insulin can be difficult. In addition, patients now have alternatives to insulin therapy thanks to the development of non-insulin injectables and oral anti-diabetic drugs, which has an impact on the need for human insulin.
The COVID-19 pandemic caused supply chains around the world to be disrupted, which affected the human insulin industry. The manufacture, distribution, and accessibility of items containing human insulin were impacted by trade restrictions, lockdown procedures, and restricted manufacturing capacity. Interruptions in the supply chain made it difficult to meet the demand for insulin and caused temporary shortages. Non-urgent medical procedures and routine checkups, such as diabetes diagnoses and follow-up consultations, were delayed or cancelled as a result of the epidemic. The commencement or modification of insulin therapy for some patients was impacted by the delay in medical procedures and diagnosis, which had an effect on the demand for human insulin supplies.
According to an NIH report Weekly death registration increased by 59.1% in people with type 1 diabetes and 64.3% in people with type 2 diabetes compared to what would have been expected given death rates in the same weeks in the previous three years, according to a linked study of more than 28 million people with type 2 diabetes and more than 250 000 people with type 1 diabetes during the same period.
As a result of the war's geopolitical tensions and volatility, the area may experience an air of unpredictability. This may have an effect on market dynamics for human insulin, corporate operations, and investor confidence. Companies could take a cautious stance, which can impede the expansion and growth of the market. The violence may interrupt healthcare services and infrastructure, making it more difficult to access medical facilities and receive effective diabetes management and treatment. Patients' access to human insulin and other diabetes-related products may be hampered by population shifts, harm to medical facilities, and travel restrictions.
By Type:
Traditional human insulin
Analogue insulin
By Diabetes Type:
Type 1
Type 2
By Distribution Channel:
Hospital Pharmacy
Online pharmacy
Retails
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Regional Analysis:
Human insulin has a sizable market in North America, with the United States being the major supplier. The area has a high prevalence of diabetes, a developed healthcare system, and great skills for research and development. A growing prevalence of diabetes, technological improvements, and favourable reimbursement policies are some of the market-driving elements.
The market for human insulin is expanding significantly in the Asia-Pacific area. The market is expanding significantly, thanks in large part to nations like China, India, and Japan. The substantial number of diabetics in the area, the expanding healthcare system, and rising disposable incomes all contribute to market expansion. Additionally, the availability of generic insulin producers in nations like India increases market competition.
The well-known businesses and others include Novo Nordisk, Companion Medical Inc., Valeritas Inc., Insulet Corporation, Cellenovo, Emperra Gmbh E-Health Technologies, F Hoffmann-La Roche, Ypsomed., Tandem Diabetes Care, Medtronic Inc players are listed in the final reports.
Novo Nordisk: For people with type 1 and type 2 diabetes, Novo Nordisk Inc. march 14 2023 stated it will reduce the U.S. list price of a number of insulin medicines by up to 75%. Products include basal (long-acting), bolus (short-acting), and pre-mix insulins in pre-filled pens and vials, specifically Levemir, Novolin, NovoLog, and NovoLog Mix 70/30. In order to match the lower list prices of each individual brand of branded insulin, Novo Nordisk is likewise lowering the list prices of unbranded biologics. The new rules will be in place as of January 1, 2024.
Insulet Corporation: Bigfoot Biomedical (Bigfoot), a pioneer in creating intelligent connected injection support systems, and Insulet Corporation, the world leader in tubeless insulin pump technology with its Omnipod brand of On February 13th, 2023, it was announced that Insulet had acquired assets related to Bigfoot's pump-based automated insulin delivery (AID) technologies. Insulet spent $25 million to acquire the business, which also includes several Bigfoot patents on pumps that could be utilised in AID treatment.
The agreement also boosts Insulet's intellectual property (IP) portfolio and gives Bigfoot additional funding to extend the use of its Bigfoot Unity diabetes management system among more patients who require linked technologies for helping them administer insulin. The deal also includes fully paid-up licences between the parties in their respective business domains with respect to the purchased patents and additional Bigfoot patents.
| Report Attributes | Details |
| Market Size in 2023 | US$ 19.21 Bn |
| Market Size by 2031 | US$ 24.71 Bn |
| CAGR | CAGR of 3.2% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Traditional human insulin, Analogue insulin) • By Diabetes Type (Type 1 & type 2) • By Distribution Channel (Hospital Pharmacy, Online pharmacy & Retails) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Novo Nordisk, Companion Medical Inc., Valeritas Inc., Insulet Corporation, Cellenovo, Emperra Gmbh E-Health Technologies, F Hoffmann-La Roche, Ypsomed., Tandem Diabetes Care, Medtronic Inc |
| Key Drivers | • Positive governmental initiatives and policies. • Increasing education and awareness. |
| Market Opportunities | • Increasing Attention Paid to Diabetes Prevention and Management. |
Ans: The Human Insulin Market is to grow at 3.2% Over the Forecast Period 2024-2031.
Ans: The projected market size of the Human Insulin Market is hit USD 24.71 billion by 2031.
Ans: Novo Nordisk, Companion Medical Inc., Valeritas Inc., Emperra Gmbh E-Health Technologies, Cellenovo, Insulet Corporation, F Hoffmann-La Roche, Medronic Inc., Tandem Diabetes Care, and Ypsomed.
Ans: In 2022, analogue insulin controlled the market.
Ans: At the moment, North America controls the world market for human insulin.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Russia and Ukraine War
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Human Insulin Market Segmentation, By Type
8.1 Traditional human insulin
8.2 Analogue insulin
9. Human Insulin Market Segmentation, By Diabetes Type
9.1 Type 1
9.2 Type 2
10. Human Insulin Market Segmentation, By Distribution Channel
10.1 Hospital Pharmacy
10.2 Online pharmacy
10.3 Retails
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Human Insulin market by Country
11.2.2North America Human Insulin market by Type
11.2.3 North America Human Insulin market by Diabetes Type
11.2.4 North America Human Insulin market by Distribution Channel
11.2.5 USA
11.2.5.1 USA Human Insulin market by Type
11.2.5.2 USA Human Insulin market by Diabetes Type
11.2.5.3 USA Human Insulin market by Distribution Channel
11.2.6 Canada
11.2.6.1 Canada Human Insulin market by Type
11.2.6.2 Canada Human Insulin market by Diabetes Type
11.2.6.3 Canada Human Insulin market by Distribution Channel
11.2.7 Mexico
11.2.7.1 Mexico Human Insulin market by Type
11.2.7.2 Mexico Human Insulin market by Diabetes Type
11.2.7.3 Mexico Human Insulin market by Distribution Channel
11.3 Europe
11.3.1 Europe Human Insulin market by Country
11.3.3.2 Europe Human Insulin market by Type
11.3.3 Europe Human Insulin market by Diabetes Type
11.3.4 Europe Human Insulin market by Distribution Channel
11.3.5 Germany
11.3.5.1 Germany Human Insulin market by Type
11.3.5.2 Germany Human Insulin market by Diabetes Type
11.3.5.3 Germany Human Insulin market by Distribution Channel
11.3.6 UK
11.3.6.1 UK Human Insulin market by Type
11.3.6.2 UK Human Insulin market by Diabetes Type
11.3.6.3 UK Human Insulin market by Distribution Channel
11.3.7 France
11.3.7.1 France Human Insulin market by Type
11.3.7.2 France Human Insulin market by Diabetes Type
11.3.7.3 France Human Insulin market by Distribution Channel
11.3.8 Italy
11.3.8.1 Italy Human Insulin market by Type
11.3.8.2 Italy Human Insulin market by Diabetes Type
11.3.8.3 Italy Human Insulin market by Distribution Channel
11.3.9 Spain
11.3.9.1 Spain Human Insulin market by Type
11.3.9.2 Spain Human Insulin market by Diabetes Type
11.3.9.3 Spain Human Insulin market by Distribution Channel
11.3.10 The Netherlands
11.3.10.1 Netherlands Human Insulin market by Type
11.3.10.2 Netherlands Human Insulin market by Diabetes Type
11.3.10.3 Netherlands Human Insulin market by Distribution Channel
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Human Insulin market by Type
11.3.11.2 Rest of Europe Human Insulin market by Diabetes Type
11.3.11.3 Rest of Europe Human Insulin market by Distribution Channel
11.4 Asia-Pacific
11.4.1 Asia Pacific Human Insulin market by Country
11.4.2 Asia Pacific Human Insulin market by Type
11.4.3 Asia Pacific Human Insulin market by Diabetes Type
11.4.4 Asia-Pacific Human Insulin market by Distribution Channel
11.4.5 Japan
11.4.5.1 Japan Human Insulin market by Type
11.4.5.2 Japan Human Insulin market by Diabetes Type
11.4.5.3 Japan Human Insulin market by Distribution Channel
11.4.6 South Korea
11.4.6.1 South Korea Human Insulin market by Type
11.4.6.2 South Korea Human Insulin market by Diabetes Type
11.4.6.3 South Korea Human Insulin market by Distribution Channel
11.4.7 China
11.4.7.1 China Human Insulin market by Type
11.4.7.2 China Human Insulin market by Diabetes Type
11.4.7.1 China Human Insulin market by Distribution Channel
11.4.8 India
11.4.8.1 India Human Insulin market by Type
11.4.8.2 India Human Insulin market by Diabetes Type
11.4.8.3 India Human Insulin market by Distribution Channel
11.4.9 Australia
11.4.9.1 Australia Human Insulin market by Type
11.4.9.2 Australia Human Insulin market by Diabetes Type
11.4.9.3 Australia Human Insulin market by Distribution Channel
11.4.10 Rest of Asia-Pacific
11.4.10.1 APAC Human Insulin market by Type
11.4.10.2 APAC Human Insulin market by Diabetes Type
11.4.10.3 APAC Human Insulin market by Distribution Channel
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Human Insulin market by Country
11.5.2 The Middle East & Africa Human Insulin market by Type
11.5.3 The Middle East & Africa Human Insulin market by Diabetes Type
11.5.4 The Middle East & Africa Human Insulin market by Distribution Channel
11.5.5 Israel
11.5.5.1 Israel Human Insulin market by Type
11.5.5.2 Israel Human Insulin market by Diabetes Type
11.5.5.3 Israel Human Insulin market by Distribution Channel
11.5.6 UAE
11.5.6.1 UAE Human Insulin market by Type
11.5.6.2 UAE Human Insulin market by Diabetes Type
11.5.6.3 UAE Human Insulin market by Distribution Channel
11.5.7 South Africa
11.5.7.1 South Africa Human Insulin market by Type
11.5.7.2 South Africa Human Insulin market by Diabetes Type
11.5.7.3 South Africa Human Insulin market by Distribution Channel
11.5.8 Rest of Middle East & Africa
11.5.8.1 Rest of Middle East & Asia Human Insulin market by Type
11.5.8.2 Rest of Middle East & Asia Human Insulin market by Diabetes Type
11.5.8.3 Rest of Middle East & Africa Human Insulin market by Distribution Channel
11.6 Latin America
11.6.1 Latin America Human Insulin market by Country
11.6.2 Latin America Human Insulin market by Type
11.6.3 Latin America Human Insulin market by Diabetes Type
11.6.4 Latin America Human Insulin market by Distribution Channel
11.6.5 Brazil
11.6.5.1 Brazil Human Insulin market by Type
11.6.5.2 Brazil Africa Human Insulin market by Diabetes Type
11.6.5.3 Brazil Human Insulin market by Distribution Channel
11.6.6 Argentina
11.6.6.1 Argentina Human Insulin market by Type
11.6.6.2 Argentina Human Insulin market by Diabetes Type
11.6.6.3 Argentina Human Insulin market by Distribution Channel
11.6.7 Rest of Latin America
11.6.7.1 Rest of Latin America Human Insulin market by Type
11.6.7.2 Rest of Latin America Human Insulin market by Diabetes Type
11.6.7.3 Rest of Latin America Human Insulin market by Distribution Channel
12. Company profile
12.1 Novo Nordisk
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Companion Medical Inc
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Valeritas Inc
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Insulet Corporation
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Cellenovo
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Emperra Gmbh E-Health technologies
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 F Hoffmann-La Roche
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Ypsomed
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Product/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Tandem Diabetes Care
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Medtronic Inc
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
14. Used Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Healthcare Contract Management Software Market size was valued at USD 1361.5 million in 2022 and is expected to reach USD 6881.5 million by 2030 at a CAGR of 22.45% during the forecast period of 2023-2030.
The Biomarkers Market, size was estimated USD 66.8 billion in 2022 and is expected to reach USD182.6 billion by 2030 at a CAGR of 13.4% during the forecast period of 2023-2030.
The Single-use Bioprocessing Market size was estimated USD 9.1 billion in 2022 and is expected to reach USD 41.5 billion by 2030 at a CAGR of 20.9% during the forecast period of 2023-2030.
The Vitamins Market Size was valued at USD 7.41 billion in 2023, and is expected to reach USD 13.39 billion by 2031, and grow at a CAGR of 7.67% over the forecast period 2024-2031.
The Protein Purification and Isolation Market size was estimated USD 8.5 billion in 2022 and is expected to reach USD 19.1 billion by 2030 at a CAGR of 10.7%during the forecast period of 2023-2030.
The Fill-Finish Manufacturing Market Size was valued at USD 9.44 billion in 2022 and is expected to reach USD 20.39 billion by 2030, and grow at a CAGR of 10.1% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
